中新网北京4月11日电 记者张尼报道，国家医疗保障局今日在京召开新闻发布会，针对外界关于集中采购（集采）政策可能抑制医药企业创新的担忧，医药价格和招标采购司司长丁一磊明确表示，高价药品并不必然代表真正的创新，集采制度实际上有助于营造公平竞争环境，重塑行业生态。
丁一磊在发布会上指出，有人认为集采会导致企业利润减少，进而影响医药企业的创新和研发动力。然而，他反驳了这一观点，强调高价格并不等同于医药创新的质量。他表示，集采政策通过市场竞争机制，鼓励企业以质量和性价比取胜，而非单纯依赖高价维持利润空间。
他进一步解释，集采可以降低药品价格，减轻患者经济负担，同时，通过公平竞争，促使企业将更多的资源投入到真正有价值的创新研发中。他认为，这种改革有利于医药行业的长期健康发展，而非短视的利润追求。
国家医保局表示，将持续推进集采工作，既要确保患者能够用上质优价廉的药品，也要保障医药企业有足够动力进行创新研发。未来，医保政策将更加注重平衡各方利益，推动医药产业的创新和可持续发展。
英语如下：
Title: “China’s Medical Insurance Bureau Dispels Concerns Over Bulk Procurement: High Prices Don’t Guarantee Innovation, Fair Competition Boosts Pharmaceutical Industry Development”
Keywords: Bulk procurement in medical insurance, price versus innovation, industry ecology
News Content:
BEIJING, April 11 (Xinhua) – By Zhang Ni, reporter – The National Medical Insurance Bureau (NMIB) held a press conference in Beijing today, emphasizing that its bulk procurement policy does not undermine pharmaceutical innovation and rebutting the notion that high prices equate to genuine innovation.
Director of the Department of Pharmaceutical Prices and Bidding Procurement, Ding Yilei, clarified that expensive drugs do not necessarily signify authentic innovation. The bulk procurement system, he argued, actually fosters a level playing field and reshapes the industry landscape.
Ding pointed out that some have argued that bulk procurement could lead to reduced corporate profits, thereby affecting the innovation and R&D motivation of pharmaceutical companies. However, he countered this view, stating that high prices are not synonymous with the quality of医药 innovation. The policy, he explained, promotes competition based on quality and cost-effectiveness, rather than relying solely on high prices to maintain profit margins.
He further elaborated that bulk procurement reduces drug prices, easing patients’ financial burdens. Simultaneously, it encourages companies to allocate more resources to genuinely valuable innovation through fair competition. Ding believes that such reforms benefit the long-term healthy development of the pharmaceutical industry, rather than short-term profit pursuits.
The NMIB affirmed its commitment to advancing bulk procurement efforts, ensuring patients have access to high-quality, affordable medicines while preserving pharmaceutical enterprises’ incentives for innovation and R&D. In the future, medical insurance policies will focus more on balancing stakeholders’ interests, fostering innovation and sustainable growth in the pharmaceutical sector.
【来源】http://www.chinanews.com/cj/2024/04-11/10196795.shtml
Views: 1